Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women
- 1.3k Downloads
The objective of this paper was to evaluate the relationship between urinary concentrations of InsP6, bone mass loss and risk fracture in postmenopausal women.
Materials and methods
A total of 157 postmenopausal women were included in the study: 70 had low (≤0.76 μM), 42 intermediate (0.76–1.42 μM) and 45 high (≥1.42 μM) urinary phytate concentrations. Densitometry values for neck were measured at enrollment and after 12 months (lumbar spine and femoral neck), and 10-year risk fracture was calculated using the tool FRAX®.
Individuals with low InsP6 levels had significantly greater bone mass loss in the lumbar spine (3.08 ± 0.65 % vs. 0.43 ± 0.55 %) than did those with high phytate levels. Moreover, a significantly greater percentage of women with low than with high InsP6 levels showed more than 2 % of bone mass loss in the lumbar spine (55.6 vs. 20.7 %). The 10-year fracture probability was also significantly higher in the low-phytate group compared to the high-phytate group, both in hip (0.37 ± 0.06 % vs 0.18 ± 0.04 %) and major osteoporotic fracture (2.45 ± 0.24 % vs 1.83 ± 0.11 %).
It can be concluded that high urinary phytate concentrations are correlated with reduced bone mass loss in lumbar spine over 12 months and with reduced 10-year probability of hip and major osteoporotic fracture, indicating that increased phytate consumption can prevent development of osteoporosis.
KeywordsBone mass loss Bone mineral density Osteoporosis Phytate Risk of fracture
Selective estrogen receptor modulators
US food and drug administration
Receptor activator for nuclear factor κ B ligand
Hormone replacement therapy
Myo-inositol hexaphosphate, phytate
Bone mineral density
F.T. thanks the Ministerio de Ciencia e Innovación de España for a Torres Quevedo contract. This work was supported by the Conselleria d’Innovacio i Energia del Govern de les Illes Balears and by project grant no. CTQ2010-18271 from the Ministerio de Ciencia y Tecnologia de España.
Conflict of interest
F.G. and J.P. declare that they are inventors of a pending patent application based on some aspects of this work. F.T. is employee at Laboratoris Sanifit. J.P. is employee and stockholder at Laboratoris Sanifit.
- 1.Kanis JA, Gluer CC (2000) An update on the diagnosis and assessment of osteoporosis with densitometry. Comm Sci Advisors Int Osteoporos Int 11:92–202Google Scholar
- 8.Pak CYC, Sakhaee K, Adamshuet B, Piziak V et al (1995) Treatment of postmenopausal osteoporosis with slow-release sodium-fluoride. Ann Intern Med 123:401–408Google Scholar
- 20.Hawkins PT, Poyner DR, Jackson TR, Letcher AJ et al (1993) Inhibition of iron-catalyzed hydroxyl radical formation by inositol polyphosphates—a possible physiological-function for myo-inositol hexakisphosphate. Biochem J 294:929–934Google Scholar
- 24.Shamsuddin AM, Von Fraunhofer JA (2007) Decreasing titratable acidity of foodstuff or beverage, e.g. nutrient-enriched drinks, used to treat and prevent degeneration of teeth and other bones, involves depositing inositol phosphate composition into foodstuff or beverage. Patent. WO2007103110-A2Google Scholar
- 28.Conte A, Piza P, Garcia-Raja A, Grases F et al (1999) Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol 52:305–310Google Scholar